Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

RenovoRx, Inc. - Common Stock (NQ: RNXT )

1.040 +0.010 (+0.97%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about RenovoRx, Inc. - Common Stock

< Previous 1 2 3 Next >
RenovoRx Highlights Promising Pre-Clinical Data Abstract: TAMP™ Therapy Platform Offers Potential to Improve Localized and Targeted Drug Delivery
From RenovoRx, Inc
Via Business Wire
BioMedNewsBreaks – RenovoRx Inc. (NASDAQ: RNXT) Announces $12.1M Underwritten Public Offering
Via Investor Brand Network
Exposures Product Safety
RenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common Stock
From RenovoRx, Inc.
Via Business Wire
RenovoRx Announces Pricing of $12.1 Million Underwritten Public Offering of Common Stock
From RenovoRx, Inc.
Via Business Wire
RenovoRx Announces Proposed Public Offering
From RenovoRx, Inc.
Via Business Wire
RenovoRx Highlights Promising Pharmacokinetic Data Abstract Presented at ASCO GI 2025
From RenovoRx, Inc.
Via Business Wire
RenovoRx Announces Acceptance of Abstract for Presentation at ASCO Gastrointestinal Cancers Symposium 2025
From RenovoRx, Inc.
Via Business Wire
RenovoRx Continues to Grow Intellectual Property Portfolio for its Novel Drug-Delivery Therapy Platform
From RenovoRx, Inc.
Via Business Wire
RenovoRx CEO Issues Update Letter to Shareholders
From RenovoRx, Inc.
Via Business Wire
Publication of Results of Pre-Clinical Studies Support Efficacy and Drug Delivery Mechanism Potential of RenovoRx’s TAMP™ Therapy Platform to Improve Targeted Cancer Drug Treatment Delivery
From RenovoRx, Inc.
Via Business Wire
RenovoRx to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase on May 21, 2024
From RenovoRx, Inc.
Via Business Wire
RenovoRx CEO Shaun R. Bagai to Present at the Aegis Capital Virtual Conference on May 9, 2024
From RenovoRx, Inc.
Via Business Wire
RenovoRx Regains Compliance with Nasdaq Stockholders’ Equity Requirement
From RenovoRx , Inc.
Via Business Wire
RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting
From RenovoRx, Inc.
Via Business Wire
RenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026
From RenovoRx, Inc.
Via Business Wire
RenovoRx Announces $11.1 Million at Market Private Placement
From RenovoRx, Inc.
Via Business Wire
RenovoRx to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 15, 2024
From RenovoRx, Inc.
Via Business Wire
RenovoRx to Present at the 36th Annual ROTH Conference on March 19, 2024
From RenovoRx, Inc.
Via Business Wire
RenovoRx Highlights Key Leadership Promotions
From RenovoRx, Inc.
Via Business Wire
RenovoRx CEO Issues Letter to Shareholders
From RenovoRx, Inc.
Via Business Wire
RenovoRx Closes $6.1 Million Private Placement
From RenovoRx, Inc.
Via Business Wire
Clinical Trials at Major University; New Application Targeting Tumors with an IP Portfolio of 9 Patents Issued, 9 Pending for Cancer Treatments Partnered with Imugene: RenovoRx (NASDAQ: RNXT)
Via Get News
Topics Intellectual Property
Exposures Intellectual Property
RenovoRx (NASDAQ: RNXT) Elevates IP Portfolio with New Application and Advances Cancer Treatments in Phase 3 Clinical Trials
Via Get News
Topics Intellectual Property
Exposures Intellectual Property
RenovoRx Engages Oklahoma University (OU) Health as First Clinical Site in Preparation for the Pivotal Phase III CouGar Clinical Trial in Bile Duct Cancer
From RenovoRx, Inc.
Via Business Wire
RenovoRx Announces Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting
From RenovoRx, Inc.
Via Business Wire
RenovoRx Files New International Patent for Novel Targeted Combination Drug-Delivery Oncology Therapy Platform
From RenovoRx, Inc.
Via Business Wire
Biopharma Company Reaches Phase 3 Clinical Trials for Cancer Treatments; 9 Patents Issued; Collaboration with Imugene: RenovoRx (NASDAQ: RNXT)
Via Get News
Topics Intellectual Property
Exposures Intellectual Property
RenovoRx Expands Scientific Advisory Board with Appointment of Michel Ducreux, M.D., Ph.D.
From RenovoRx, Inc.
Via Business Wire
RenovoRx Reports Third Quarter 2023 Financial Results and Operational Highlights
From RenovoRx, Inc.
Via Business Wire
RenovoRx to Present at the ROTH MKM Healthcare Opportunities Conference on October 12, 2023
From RenovoRx, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS